No Data
Sailong Pharmaceutical Group (002898.SZ): Participating in the tenth batch of national Pharmaceutical centralized procurement, expected to win the bid.
On December 13, Glonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical (Changsha) Co., Ltd. (hereinafter referred to as "Changsha Sailong") participated in the bidding work organized by the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the tenth batch of national centralized procurement of pharmaceuticals. Some of the company's products are expected to win bids in this centralized procurement.
Sailong Pharmaceutical Group (002898.SZ) has obtained the supplementary approval letter for Pregabalin Capsules.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently received...
Sailong Pharmaceutical Group (002898.SZ): Sailong Polaris has cumulatively reduced its shareholding by 1%.
On November 4th, Geronghui reported that Sailong Pharmaceutical Group (002898.SZ) recently received a notification letter from shareholder Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., holding more than 5% of the shares, about the change in equity reaching 1%. It was learned that following the company's previous disclosure of the announcement of shareholders reducing their holdings by more than 1%, Sailong Juzhi reduced the company's shares by 130,000 shares through centralized auction trading from November 26, 2022, to November 28, 2022, between May 4, 2023, and June 2, 2023, through centralized auction trading.
Cailong Pharmaceuticals: Report for the third quarter of 2024
Sailong Pharmaceutical Gets Approval Notice for Fluorouracil Listing
Sailong Pharmaceutical Group (002898.SZ): Subsidiary has obtained the approval notice for the application for listing of chemical raw materials.
On September 25th, Gelonhui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the National Medical Products Administration's approval and issuance of the approval notice for the listing application of hydrochloride esmolol as an active pharmaceutical ingredient. The main indications for hydrochloride esmolol preparations are: used to treat paroxysmal supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension.
Some Confidence Is Lacking In Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) As Shares Slide 29%
No Data
